OncoHost Publishes Data Identifying Predictive Signature for Response to Immunotherapy in Lung Cancer Patients

Study Demonstrates Potential Clinical Utility of Analyzing Proteomic Changes in Plasma During ICI Therapy to Predict Individual Patient Response

News provided by

OncoHost

Sep 13, 2021, 08:00 ET

BINYAMINA, Israel, Sept. 13, 2021 /PRNewswire/ -- OncoHost, a global leader in next-generation precision oncology for improved personalized cancer therapy, has published a study identifying a predictive proteomic signature for patient response to immune checkpoint inhibitor (ICI) therapy in non-small-cell lung carcinoma (NSCLC) patients. The signature was discovered using OncoHost's first-of-its-kind, AI-based platform, PROphet^®, and the study will be presented as a poster at the ESMO Virtual Congress 2021.

Immune checkpoint inhibitor (ICI)-based treatment has revolutionized the cancer therapy landscape, displaying a significant response in patients with advanced stage disease. However, only a small fraction of patients actually responds to this treatment, making it critical to identify reliable biomarkers for response and understand the mechanisms underlying resistance. OncoHost's PROphet platform utilizes advanced machine learning and bioinformatics to analyze the complex tumor-patient-treatment biologic interplay, providing clinicians and their patients with a clinically actionable "disease navigator."

"This study has revealed that OncoHost's bioinformatic analysis and host response evaluation based on proteomic data can help predict patient outcomes with very high accuracy," said Professor Yuval Shaked, founder and Chief Scientific Advisor at OncoHost, and Professor of Cell Biology and Cancer Science at the Technion – Israel Institute of Technology. "We are proud to be taking such strides in overcoming the challenge of non-responsiveness to immunotherapy and advancing the development of novel therapeutic strategies."

Researchers examined host-mediated effects occurring in response to ICI treatment, and their contribution to therapy resistance in stage IV NSCLC patients. Overall, 108 subjects participated in the study, of whom 80 were responders and 28 were non-responders. The research revealed that plasma proteome changes occur following immunotherapy, suggesting host (patient) response to ICI treatment. An analysis of differentially expressed proteins in the patients indicated therapy-specific mechanisms of resistance.

"Traditional precision medicine searches for biomarkers at the therapy-tumor axis. By adding the patient to the equation, OncoHost is fighting cancer through a distinctive, deep profiling of the patient-tumor interface," said Dr. Ofer Sharon, CEO of OncoHost. "Our research demonstrates the potential clinical utility of PROphet, offering physicians targeted treatment options for their patients and identifying previously unanticipated targets for future interventions and clinical trials."

The clinical study was conducted in collaboration with the Chaim Sheba Medical Center Institute of Oncology, the Technion Institute of Technology, Thomas Jefferson University and the University of Connecticut.

The virtual ESMO Congress 2021 will take place September 16-21.

Poster Title: A predictive signature for response to immunotherapy in non-small cell lung cancer based on plasma proteomics and clinical parameters.
Abstract #: 300
E-poster #: 74P

The abstract is available on the ESMO website here.

About OncoHost

OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients' unique response to therapy and overcome one of the major obstacles in clinical oncology today – resistance to therapy. OncoHost's host response profiling platform, PROphet®, analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e., the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet® also identifies potential drug targets, advancing the development of novel therapeutic strategies as well as rationally based combination therapies.

For more information, visit http://www.oncohost.com.

Follow OncoHost on LinkedIn, Twitter and Facebook.

Media Contact:
FINN Partners for OncoHost
Lior Feigin
[email protected]
@LiorFeigin
+1 929 588 2016
+972-54-282-4503

SOURCE OncoHost